HSTM vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HSTM presents a contradictory profile: while the Piotroski F-Score of 7/9 indicates strong fundamental health and a clean balance sheet, the valuation is severely disconnected from intrinsic reality. The stock trades at $19.88, significantly above both its Graham Number ($12.82) and its growth-based intrinsic value ($4.27). This valuation gap is exacerbated by a collapse in earnings growth (-46.5% YoY) and a completely bearish technical trend (0/100). Despite low debt, the combination of crashing profitability and insider selling suggests a value trap scenario.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HSTM vs LLY: Head-to-Head Comparison
This page compares HealthStream, Inc. (HSTM) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.